Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 13/20 | 0.56 |
| ▸ | EGFR | P00533 | 12/20 | 0.56 |
| ▸ | JAK3 | P52333 | 2/20 | 0.46 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.45 |
| ▸ | TGM2 | P21980 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.43 |
| ▸ | TEC | P42680 | 1/20 | 0.43 |
| ▸ | TXK | P42681 | 1/20 | 0.43 |
| ▸ | BLK | P51451 | 1/20 | 0.43 |
| ▸ | BMX | P51813 | 1/20 | 0.43 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL722213 | 0.98 | BTK (0.59) | BTKEGFRJAK3ERBB2TGM2 | |
| SCHEMBL723014 | 0.94 | EGFR (0.58) | BTKEGFRJAK3TGM2KCNH2 | |
| SCHEMBL722390 | 0.92 | BTK (0.49) | BTKEGFRJAK3ERBB2TEC | |
| SCHEMBL722377 | 0.91 | EGFR (0.49) | BTKEGFRJAK3BLK | |
| SCHEMBL721787 | 0.90 | TGM2 (0.52) | BTKEGFRJAK3ERBB2TGM2 | |
| SCHEMBL723514 | 0.87 | EGFR (0.47) | BTKEGFRJAK3ERBB2PLCG1 | |
| SCHEMBL721853 | 0.87 | BTK (0.47) | BTKEGFRJAK3 | |
| SCHEMBL721852 | 0.87 | BTK (0.47) | BTKEGFRJAK3 | |
| SCHEMBL723264 | 0.85 | PLCG1 (0.51) | BTKEGFRJAK3TGM2PLCG1 | |
| SCHEMBL723784 | 0.85 | ALDH1A1 (0.53) | BTKJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2609100-B1 | FUROPYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-06-24 | — | — | EP | claimed |
| US-9006440-B2 | Furopyridine derivatives | MERCK PATENT GMBH (DE) | 2015-04-14 | — | — | US | claimed |
| US-20130225569-A1 | FUROPYRIDINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-08-29 | — | — | US | claimed |
| EP-2609100-A2 | FUROPYRIDINE DERIVATIVES | Merck Patent GmbH (DE) | 2013-07-03 | — | — | EP | claimed |
| WO-2012025187-A2 | FUROPYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2012-03-01 | — | — | WO | claimed |
| EP-2609100-B1 | FUROPYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-06-24 | — | — | EP | disclosed |
| EP-2609100-B1 | FUROPYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-06-24 | — | — | EP | disclosed |
| US-9006440-B2 | Furopyridine derivatives | MERCK PATENT GMBH (DE) | 2015-04-14 | — | — | US | disclosed |
| US-9006440-B2 | Furopyridine derivatives | MERCK PATENT GMBH (DE) | 2015-04-14 | — | — | US | disclosed |
| US-9006440-B2 | Furopyridine derivatives | MERCK PATENT GMBH (DE) | 2015-04-14 | — | — | US | disclosed |
| US-20130225569-A1 | FUROPYRIDINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-08-29 | — | — | US | disclosed |
| EP-2609100-A2 | FUROPYRIDINE DERIVATIVES | Merck Patent GmbH (DE) | 2013-07-03 | — | — | EP | disclosed |
| WO-2012025187-A2 | FUROPYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2012-03-01 | — | — | WO | disclosed |
| WO-2012025187-A2 | FUROPYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2012-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225569-A1 | FUROPYRIDINE DERIVATIVES | SYK, FCGRT, SSB | BTK 4/4885EGFR 1317/4885JAK3 154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.